Ex-Foundation Medicine CEO as director Sophia Genetics taps


The previous CEO of the atomic testing organization Foundation Medicine, Troy Cox, has been named administrator of the Swiss enormous information firm Sophia Genetics subsequent to serving on its top managerial staff for not exactly a year.

First joining the organization last July, Cox will currently take over from Antoine Duchateau beginning March 1. Duchateau, who has filled in as director since 2013, will remain on as a board part.

“This announcement signals how much of an asset Troy has been for SOPHiA GENETICS in this short amount of time,” prime supporter and CEO Jurgi Camblong said in an announcement.

“I am delighted that he will assume the chairmanship of the company’s board, as his impressive expertise will help us to further expand our community of partners and the scope of new clinical-grade applications to further the success of our mission,” Camblong included.

That is by all account not the only staff change. Simply a week ago, Camblong and Sophia Genetics offer greeting to the organization’s new boss clinical official, Philippe Menu. They joins from McKinsey and Company, where he co-drove the association’s McKinsey Cancer Center consultancy.

“I am incredibly inspired by what the SOPHiA team has already achieved by analyzing half a million patients’ genomic profiles across the world through its unique and growing global network of hospital partners,” Menu said.

“Looking ahead, I am most impressed by the full potential to positively impact patients’ lives that still lies ahead of us through the application of SOPHiA’s multi-modal data approach.”

The Lausanne, Switzerland-based Sophia Genetics has been hoping to extend globally over the previous year—following its $77 million arrangement E round in January 2019—and bring its man-made brainpower based stage to more clinic frameworks.

The organization’s investigation hopes to employ genomic and radiomic information to help determine patients to have malignant growth and uncommon inherited issue. Presently, Sophia Genetics says it can use more multi-modular information, to help control accuracy medications.

Those thoughts are the same old thing for Cox, who, before filling in as CEO of Foundation Medicine during its procurement by Roche, held senior VP positions at Genetic and Sanofi.

“I’m proud to take a leadership role at this important time of expansion and to be part of SOPHiA GENETICS mission,” Cox said.

“Thanks to its global and universal approach that already benefits more than 1,000 hospital partners, SOPHiA is uniquely positioned to lead and promote an important movement in the entire ecosystem.”

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Daily Digital Health journalist was involved in the writing and production of this article.